首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1547537

全球呼吸道病毒疫苗市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Respiratory Virus Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 222 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球呼吸道病毒疫苗市場需求預計將從2023年的109.5億美元達到2032年近229.2億美元的市場規模，2024-2032年研究期間的複合年成長率為8.55%。

疫苗是一種生物製劑，用於提供針對多種有害病原體的後天免疫力。它的目的是預防弱勢群體罹患某種特定疾病。它含有一種病原體，即細菌或病毒株，能以弱化或去活化的形式引起特定疾病。呼吸系統疾病是一種影響肺部和身體呼吸系統其他部位的疾病。它可能是由於吸煙、被動吸煙、感染、石棉和其他類型的空氣污染引起的。呼吸系統疾病包括氣喘、肺纖維化、肺炎、慢性阻塞性肺病和肺癌。特定的疫苗可預防疾病會導致氣道和肺部腫脹。兩者混合會引發肺炎和各種真正的呼吸道疾病。免疫接種被認為是確保個人健康的最安全方法，無論患者是否服用處方藥物。疫苗反應通常很輕微，並且會自行消失。嚴重的副作用極為罕見。

市場動態

該市場的推動因素包括呼吸道疾病盛行率的上升和試驗中疫苗數量的增加，而交付基礎設施不足和消費者意識有限是限制因素。透過各種市場合作增加研發支出和增加疫苗供應，為市場成長創造了機會。此外，呼吸道疫苗的研發目前主要集中在COVID-19；然而，長期前景仍然樂觀。從 COVID-19 的影響中汲取經驗，全球各國政府致力於開發適當的呼吸道疫苗治療方案。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球呼吸道病毒疫苗市場的各個細分市場進行了包容性評估。呼吸道病毒疫苗產業的成長和趨勢為本研究提供了整體方法。

市場區隔

呼吸道病毒疫苗市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按類型

失活/殺死
疫苗
減毒活疫苗
重組疫苗

依給藥途徑

肌肉注射
鼻內
皮下

按指示

流感
麻疹、腮腺炎和德國麻疹
冠狀病毒病（COVID-19）
其他

按年齡段

兒科
成年人

按最終用戶

醫生辦公室
醫院
診所
藥房/商店

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲呼吸道病毒疫苗市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。呼吸道病毒疫苗市場的主要參與者包括 CSL Limited、賽諾菲、阿斯特捷利康、默克公司、葛蘭素史克公司、印度血清研究所。有限公司、巴拉特生物技術公司、科興生物技術有限公司。開發、新產品發布，以及其他進度。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 按類型分類的市場吸引力分析
- 按給藥途徑進行的市場吸引力分析
- 按指標進行的市場吸引力分析
- 按年齡層別分類的市場吸引力分析
- 最終用戶的市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球呼吸道病毒疫苗市場分析：按類型

按類型概述
按類型分析歷史和預測數據
失活/殺死
疫苗
減毒活疫苗
重組疫苗

第 6 章：全球呼吸道病毒疫苗市場分析：依給藥途徑

依給藥途徑概述
按給藥途徑進行歷史和預測資料分析
肌肉注射
鼻內
皮下

第 7 章：全球呼吸道病毒疫苗市場分析：依適應症分類

按指示概述
按指示進行歷史和預測資料分析
流感
麻疹、腮腺炎和德國麻疹
冠狀病毒病（COVID-19）
其他

第 8 章：全球呼吸道病毒疫苗市場分析：依年齡層別分類

按年齡層別概述
按年齡層別進行的歷史和預測資料分析
兒科
成年人

第 9 章：全球呼吸道病毒疫苗市場分析：依最終用戶分類

最終用戶概述
最終用戶的歷史和預測數據分析
醫生辦公室
醫院
診所
藥房/商店

第 10 章：全球呼吸道病毒疫苗市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 11 章：呼吸道病毒疫苗公司的競爭格局

呼吸道病毒疫苗市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 12 章：公司簡介

頂級公司市佔率分析
市場集中度
CSL Limited

公司概況
公司收入
產品
最新動態

Sanofi

公司概況
公司收入
產品
最新動態

AstraZeneca

公司概況
公司收入
產品
最新動態

Merck & Co. Inc.

公司概況
公司收入
產品
最新動態

GlaxoSmithKline Plc

公司概況
公司收入
產品
最新動態

Serum Institute Of India Pvt. Ltd.

公司概況
公司收入
產品
最新動態

Bharat Biotech

公司概況
公司收入
產品
最新動態

Sinovac Biotech Ltd

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11215029

The global demand for Respiratory Virus Vaccines Market is presumed to reach the market size of nearly USD 22.92 Billion by 2032 from USD 10.95 Billion in 2023 with a CAGR of 8.55% under the study period 2024-2032.

A vaccine is a biological preparation that is used to provide acquired immunity against numerous harmful pathogens. It is administered to prevent the vulnerable population from a specific disease. It contains an agent, i.e., bacteria or virus strain, which causes a particular disease in a weakened or killed form. Respiratory disease is a disease that impacts the lungs and other parts of the body's respiratory system. It can be caused due to smoking, passive smoking, infection, asbestos, and another type of air pollution. Respiratory diseases consist of asthma, pulmonary fibrosis, pneumonia, COPD, and lung cancer COPD and asthma cause breathing difficulty due to swelling of the air passage and blockage due to mucus. Specific vaccine-preventable diseases can cause swelling of air passage and lungs. The mixing of the two can prompt pneumonia and various genuine respiratory diseases. Immunization is considered the most secure way to ensure a person's wellbeing, regardless of whether the sufferer is taking prescribed medications. Vaccine reactions are generally mild and fade away on their own. Serious side effects are exceptionally uncommon.

MARKET DYNAMICS

The market is driven by factors such as the increasing prevalence of respiratory diseases and the increasing number of under-trial vaccines, whereas lack of inadequate delivery infrastructure and limited consumer awareness are restraining factors. Increasing expenditure on Research & Development and the growing availability of vaccines through various market collaborations create opportunities for market growth. In addition, R&D on respiratory vaccines is focused on COVID-19 at the moment; however, the long-term outlook remains positive. Learning from the impact of COVID-19, governments across the globe focus on developing adequate treatment options for respiratory vaccines.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Respiratory Virus Vaccines. The growth and trends of Respiratory Virus Vaccines industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Respiratory Virus Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Inactivated/Killed
Vaccines
Live-attenuated Vaccines
Recombinant Vaccines

By Route of Administration

Intramuscular
Intranasal
Subcutaneous

By Indication

Influenza
Measles, Mumps & Rubella
Coronavirus Disease (COVID-19)
Others

By Age Group

Pediatric
Adults

By End User

Physician's Office
Hospitals
Clinics
Pharmacies/Stores

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Respiratory Virus Vaccines market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Respiratory Virus Vaccines market include CSL Limited, Sanofi, AstraZeneca, Merck & Co. Inc., GlaxoSmithKline Plc, Serum Institute Of India Pvt. Ltd., Bharat Biotech, Sinovac Biotech Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RESPIRATORY VIRUS VACCINES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Age Group
- 3.7.5 Market Attractiveness Analysis By End User
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Inactivated/Killed Historic and Forecast Sales By Regions
5.4. Vaccines Historic and Forecast Sales By Regions
5.5. Live-attenuated Vaccines Historic and Forecast Sales By Regions
5.6. Recombinant Vaccines Historic and Forecast Sales By Regions

6. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Intramuscular Historic and Forecast Sales By Regions
6.4. Intranasal Historic and Forecast Sales By Regions
6.5. Subcutaneous Historic and Forecast Sales By Regions

7. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY INDICATION

7.1. Overview By Indication
7.2. Historical and Forecast Data Analysis By Indication
7.3. Influenza Historic and Forecast Sales By Regions
7.4. Measles, Mumps & Rubella Historic and Forecast Sales By Regions
7.5. Coronavirus Disease (COVID-19) Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY AGE GROUP

8.1. Overview By Age Group
8.2. Historical and Forecast Data Analysis By Age Group
8.3. Pediatric Historic and Forecast Sales By Regions
8.4. Adults Historic and Forecast Sales By Regions

9. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY END USER

9.1. Overview By End User
9.2. Historical and Forecast Data Analysis By End User
9.3. Physician's Office Historic and Forecast Sales By Regions
9.4. Hospitals Historic and Forecast Sales By Regions
9.5. Clinics Historic and Forecast Sales By Regions
9.6. Pharmacies/Stores Historic and Forecast Sales By Regions

10. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE RESPIRATORY VIRUS VACCINES COMPANIES

11.1. Respiratory Virus Vaccines Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF RESPIRATORY VIRUS VACCINES INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. CSL Limited
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Sanofi
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. AstraZeneca
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. Merck & Co. Inc.
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. GlaxoSmithKline Plc
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. Serum Institute Of India Pvt. Ltd.
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Bharat Biotech
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Sinovac Biotech Ltd
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments